Trials / Completed
CompletedNCT01942733
Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To assess effects of brexpiprazole on sleep patterns of depressed patients with sleep disturbances.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brexpiprazole | 2-3 mg/day, once daily, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgment. |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2013-09-16
- Last updated
- 2019-03-20
- Results posted
- 2016-03-01
Source: ClinicalTrials.gov record NCT01942733. Inclusion in this directory is not an endorsement.